Sunitinib vs. interferon-alpha (IFN-alpha) in first-line metastatic renal cell carcinoma (mRCC): An economic evaluation

被引：1
|
作者：
Remak, E. [1 ]
Brown, R. [2 ]
Negrier, S. [3 ]
Motzer, R. J. [4 ]
Kim, S. T. [5 ]
Charbonneau, C. [6 ]
机构：
[1] United Biosource Corp, Budapest, Hungary
[2] United Biosource Corp, London, England
[3] Ctr Leron Berard, Lyon, France
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Pfizer Inc, San Diego, CA USA
[6] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)65176-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A327 / A328
页数：2
相关论文
共 50 条
  • [1] Economic evaluation of sunitinib vs. interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
    Negrier, S.
    Remak, E.
    Brown, R.
    Kim, S. T.
    Charbonneau, C.
    Motzer, R. J.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 303 - 303
  • [2] Economic evaluation of sunitinib vs. interferon-alfa (IFN-alfa) in first-line treatment of Metastatic Renal Cell Carcinoma (MRCC) in Colombia
    Godoy, J., I
    Cardona, A. F.
    Alvis, N.
    Arango, C. H.
    Romero, M.
    Spath, A.
    Ramirez, P.
    Caceres, H. A.
    Quijano, M. F.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A100 - A100
  • [3] Sunitinib vs. Interferon-alpha zur Behandlung des metastasierten NierenzellkarzinomsSunitinib vs interferon-alpha for the treatment of metastatic renal cell carcinoma
    C. Doehn
    [J]. Der Onkologe, 2007, 13 (9): : 862 - 864
  • [4] Economic evaluations of sunitinib versus interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
    Remak, E.
    Mullins, C. D.
    Akobundu, E.
    Charbonneau, C.
    Woodruff, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Negrier, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 190 - 190
  • [6] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Negrier, S.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON-ALFA (IFN-□) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)
    Szczylik, C.
    Negrier, S.
    Oudard, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I
    Motzer, R. J.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 182 - 182
  • [8] ECONOMIC EVALUATION OF SUNITINIB, SORAFENIB, BEVACIZUMAB/INTERFERON ALPHA AND TEMSIROLIMUS IN FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ISRAEL
    Greenberg, D.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A42 - A42
  • [9] Metastatic renal cell carcinoma: a comparative effectiveness assessment of first-line bevacizumab plus Interferon alpha-2a vs sunitinib
    Mickisch, G. H.
    Schwander, B.
    Walzer, S.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 437 - 437
  • [10] A COMPARATIVE EFFECTIVENESS ASSESSMENT OF FIRST-LINE BEVACIZUMAB plus INTERFERON ALPHA-2A VS SUNITINIB IN METASTATIC RENAL CELL CARCINOMA
    Mickisch, G. H.
    Schwander, B.
    Escudier, B.
    Bellmunt, J.
    Maroto, P.
    Porta, C.
    Walzer, S.
    Siebert, U.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A258 - A258
12345